Literature DB >> 18426366

Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research.

Anthony S Fauci1.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18426366     DOI： 10.1086/587904

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  44 in total

Review 1.  Immune regulatory activities of early secreted antigenic target of 6-kD protein of Mycobacterium tuberculosis and implications for tuberculosis vaccine design.

Authors:  Buka Samten; Xisheng Wang; Peter F Barnes
Journal:  Tuberculosis (Edinb)       Date:  2011-12-09       Impact factor: 3.131

Review 2.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

3.  In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France.

Authors:  Sirwan Muhammed Ameen; Michel Drancourt
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

4.  Drug-resistant tuberculosis in sub-saharan Africa.

Authors:  Jeffrey Hafkin; Victoria M Gammino; Joseph J Amon
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

5.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 6.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 7.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

8.  The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin.

Authors:  Radhika Gupta; Marie Lavollay; Jean-Luc Mainardi; Michel Arthur; William R Bishai; Gyanu Lamichhane
Journal:  Nat Med       Date:  2010-03-21       Impact factor: 53.440

Review 9.  Priorities for tuberculosis research: a systematic review.

Authors:  Jamie Rylance; Madhukar Pai; Christian Lienhardt; Paul Garner
Journal:  Lancet Infect Dis       Date:  2010-11-01       Impact factor: 25.071

10.  Essential metabolites of Mycobacterium tuberculosis and their mimics.

Authors:  Gyanu Lamichhane; Joel S Freundlich; Sean Ekins; Niluka Wickramaratne; Scott T Nolan; William R Bishai
Journal:  mBio       Date:  2011-02-01       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.